157 related articles for article (PubMed ID: 2786553)
1. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
7. Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Poiesz BJ; Comis RL
J Biol Response Mod; 1989 Aug; 8(4):359-65. PubMed ID: 2666585
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
[TBL] [Abstract][Full Text] [Related]
11. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 and lymphokine activated killer cells: promises and cautions.
Glassman AB
Ann Clin Lab Sci; 1989; 19(1):51-5. PubMed ID: 2644890
[TBL] [Abstract][Full Text] [Related]
13. [Interleukin-2 based immunotherapy of cancer].
Geertsen PF; Hermann GG; Claësson MH; Steven K; Zeuthen J; von der Maase H
Ugeskr Laeger; 1990 Nov; 152(47):3513-7. PubMed ID: 2256204
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of natural human interferon beta in metastatic malignancy.
Bukowski RM; Sergi JS; Sharfman WJ; Budd GT; Murthy S; Barna B; Medendorp SV; Yen-Lieberman B; Gibson V; Bauer L
Cancer Res; 1991 Feb; 51(3):836-40. PubMed ID: 1988123
[TBL] [Abstract][Full Text] [Related]
15. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of interleukin-2 in children with cancer.
Roper M; Smith MA; Sondel PM; Gillespie A; Reaman GH; Hammond GD; Levitt D; Rosolen A; Colamonici OR; Neckers LM
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):305-11. PubMed ID: 1456395
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results.
Sarna GP; Figlin RA; Pertcheck M; Altrock B; Kradjian SA
J Biol Response Mod; 1989 Feb; 8(1):16-24. PubMed ID: 2784163
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.
Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI
Leukemia; 1992 Mar; 6(3):220-3. PubMed ID: 1564960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]